REPLIGEN CORP
RGEN · Biological Products, (No Disgnostic Substances)
Latest available SEC filing: 10-Q ·
Latest disclosures
-
Latest financial period: Q3 2026
Financial facts · Filed
-
Form 10-Q
SEC filing · Filed
-
Douglass Brian Robb: Form 4
Insider disclosure · Filed · Report period 06 Oct 2026
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
- RGEN · 759916109 - COMMON STOCK
Company details and SEC sources
CIK 0000730272 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- RGEN on Nasdaq
- SEC industry group
- Biological Products, (No Disgnostic Substances) (Office of Life Sciences)
- Business address
- 41 Seyon Street, Building 1, Suite 100, Waltham, MA, 02453
- Incorporated in
- DE
- Fiscal year end
- 31 December
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields